Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This concise book serves as a practical primer for the care of patients with primary brain tumors. Divided into two major sections, the first provides chapters with key information for each major brain tumor type. This includes basic information about etiology, epidemiology, clinical features, pathology, imaging, diagnostic workup, and treatment. The second section of the book features chapters that delve into supportive care management with specifics about management for each of the major conditions. This includes tumor-related epilepsy, venous thromboembolism in brain tumor patients, and corticosteroid management and toxicity. Detailed and clinically-focused information about chemotherapy regimens, dosing, monitoring, management of toxicities and patient education are also provided. Brain Tumors is a quick resource in the inpatient setting or in the clinic and educational resource to help new providers in the neuro-oncology field with the accumulated knowledge of clinicians with practical experience. .

Neurology. --- Internal medicine. --- Internal Medicine. --- Brain Neoplasms. --- Antineoplastic Agents. --- Drug-Related Side Effects and Adverse Reactions --- Radiotherapy --- adverse events. --- Brain --- Tumors.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Cancer remains one of the main causes of morbidity and mortality worldwide. Although many pharmacological and clinical advances have been made, there is a constant need for new molecules to improve the overall options for treatment. Natural compounds from animal, microbial, vegetal, or fungal origin represent countless sources of new compounds that can be used as anticancer drugs, provided their activity, bioavailability, and toxicity are adequate. This book aims to compile both original articles and reviews that cover the most recent advances in the use of natural compounds for cancer treatment, and provide new objectives and advice for future research in the field of biological activity of natural compounds.

microbiota --- treatment --- n/a --- sulforaphane --- synergy --- epigenetic --- natural compound --- xenohormesis --- anticancer --- miR-663 --- tyrosine kinase inhibitors --- acetylation --- epidemiology --- double-blinded --- inflammation --- bladder cancer --- polypharmacology --- animal model --- synbiotics --- resveratrol --- royal jelly --- 5-aza-2’-deoxycytine --- saponins --- phenolics --- cardiovascular disease --- antioxidant --- colorectal cancer --- trypsin inhibitors --- seeds --- green tea --- Gac --- randomized clinical trial --- melanoma --- adverse events --- extraction --- microbiome --- Momordica cochinchinensis --- freeze dried extract --- renal cell carcinoma --- methylation --- cancer --- probiotics --- 5-aza-2'-deoxycytine

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Over the last few decades, remarkable progress has been made in understanding the aetiology and pathophysiology of diseases and many new theories emphasize the importance of the small bowel ‘ecosystem’ in the pathogenesis of acute and chronic illness. Emerging factors such as microbiome, stem cells, innate intestinal immunity and the enteric nervous system along with mucosal and endothelial barriers have key role in the development of gastrointestinal and extra-intestinal diseases. Therefore, the small intestine is considered key player in metabolic disease development, including diabetes mellitus, and other diet-related disorders such as celiac and non-celiac enteropathies. Another major field is drug metabolism and its interaction with microbiota. Moreover, the emergence of gut-brain, gut-liver and gut-blood barriers points toward the important role of small intestine in the pathogenesis of common disorders, such as liver disease, hypertension and neurodegenerative disease. However, the small bowel remains an organ that is difficult to fully access and assess and accurate diagnosis often poses a clinical challenge. Eventually, the therapeutic potential remains untapped. Therefore, it is due time to direct our interest towards the small intestine and unravel the interplay between small-bowel and other gastrointestinal (GI) and non-GI related maladies.

capsule endoscopy --- Crohn’s disease --- mucosal healing --- small bowel --- gut brain axis --- microbiota --- functional gastrointestinal disorders --- inflammatory bowel disease (IBD) --- adult stem cells --- surgical site infections (SSIs) --- probiotics --- prebiotics --- synbiotics --- surgery --- adverse events --- meta-analysis --- systematic review --- hyperspectral imaging --- multispectral imaging --- clinical diagnosis --- biomedical optical imaging --- gastroenterology --- medical diagnostic imaging --- small-bowel mass --- small-bowel bulge --- video capsule endoscopy --- cystic fibrosis --- gut microbiota --- intestinal inflammation --- fecal calprotectin --- dysbiosis index --- celiac disease --- biomarker --- serology --- enteropathy --- n/a --- colon cancer --- cancer risk --- collagenous colitis --- lung cancer --- microscopic colitis --- skin cancer --- squamous cell carcinoma --- Crohn's disease

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed. Cancer cases that were highly responsive to gefitinib were later discovered to have epithelial growth factor receptor (EGFR) mutations. This discovery opened the door for biomarker-based treatment strategies. Subsequently, several EGFR-tyrosine kinase inhibitors (TKI) were developed, and they became a new mainstay of treatment for non-small cell lung cancer. In recent years, many mechanisms of resistance to EGFR-TKI have been elucidated; a mutation in the T790M gene at exon 20 is found in half of the resistant cases. Hence, osimertinib, which specifically inhibits EGFR despite this T790M gene mutation, was developed to achieve long-term progression-free survival. Other driver mutations that are similar to the EGFR mutation were discovered, including the EML4-ALK fusion gene (discovered in 2007), ROS1 gene, and BRAF gene mutations. The TKIs for each of these fusion genes were developed and are used as therapeutic agents. Another advancement in advanced non-small cell lung cancer is the development of immune checkpoint inhibitors. Four PD-1/PD-L1 inhibitors, including nivolumab, are currently available for treatment of lung cancer. These drugs prevent an escape from the cancer immunity cycle. This ensures that cancer cells will express cancer antigens, causing an anticancer immune response. Due to cancer immunotherapy, long-term survival is possible. The biomarker development for cancer immunotherapy and its side effects are actively being studied.

non-small cell lung cancer --- previously treated patients --- phase I/II trial --- chemotherapy --- docetaxel --- S-1 --- immunotherapy --- rechallenge --- retrospective analysis --- pulmonary pleomorphic carcinoma --- prognostic factor --- glucose transporter 1 --- lung cancer --- multiple cancers --- metastasis --- sequencing --- mutation --- genomic diagnosis --- FDG-PET --- immune checkpoint inhibitor --- PD-1 --- prognosis --- RAD51B methylation --- PD-L1 expression --- predictive biomarker --- PD-1 blockade --- interstitial lung disease --- pulmonary fibrosis --- radiology and other imaging --- non-small-cell lung cancer --- epidermal growth factor receptor --- tyrosine kinase inhibitors --- TP53 mutations --- responsiveness --- targeted therapy --- network meta-analysis --- stage IIIA-N2 --- surgery --- immune checkpoint inhibitors --- biomarker --- nonsmall cell lung cancer --- HIP1R --- PD-L1 --- RUNX1 --- methylation --- survival --- EGFR-TKI --- T790M --- osimertinib --- immune-related adverse events --- endocrine disorders --- tumor-bearing patients --- PD-1 inhibitors --- PD-L1 inhibitors --- meta-analysis --- nivolumab --- Expanded Access Program --- real-world data --- daily practice --- prognostic factors --- NSCLC --- KRAS --- DNA polymerase beta --- platinum-based first-line --- adjuvant chemotherapy --- β-catenin --- lung neoplasms --- nucleotide-diphosphate kinase --- recurrence --- unresectable --- salvage surgery --- oligometastasis